Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.

Spec A, Pullman J, Thompson GR, Powderly WG, Tobin EH, Vazquez J, Wring SA, Angulo D, Helou S, Pappas PG; Mycoses Study Group .

J Antimicrob Chemother. 2019 Jul 15. pii: dkz277. doi: 10.1093/jac/dkz277. [Epub ahead of print]

PMID:
31304536
2.

A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis.

Larkin EL, Long L, Isham N, Borroto-Esoda K, Barat S, Angulo D, Wring S, Ghannoum M.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02611-18. doi: 10.1128/AAC.02611-18. Print 2019 May.

PMID:
30885896
3.

SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [14C]SCY-078 in Albino and Pigmented Rats.

Wring S, Borroto-Esoda K, Solon E, Angulo D.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e02119-18. doi: 10.1128/AAC.02119-18. Print 2019 Feb.

4.

Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus.

Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, Angulo D.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):60-69. doi: 10.1002/cpdd.588. Epub 2018 Jun 27.

PMID:
29947477
5.
6.

Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.

Van Bocxlaer K, Gaukel E, Hauser D, Park SH, Schock S, Yardley V, Randolph R, Plattner JJ, Merchant T, Croft SL, Jacobs RT, Wring SA.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02419-17. doi: 10.1128/AAC.02419-17. Print 2018 May.

7.

Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase.

Volkov OA, Brockway AJ, Wring SA, Peel M, Chen Z, Phillips MA, De Brabander JK.

J Med Chem. 2018 Feb 8;61(3):1182-1203. doi: 10.1021/acs.jmedchem.7b01654. Epub 2018 Jan 5.

8.

Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.

Thompson AM, Marshall AJ, Maes L, Yarlett N, Bacchi CJ, Gaukel E, Wring SA, Launay D, Braillard S, Chatelain E, Mowbray CE, Denny WA.

Bioorg Med Chem Lett. 2018 Jan 15;28(2):207-213. doi: 10.1016/j.bmcl.2017.10.067. Epub 2017 Oct 27.

9.

Synthesis and evaluation of analogs of 5'-(((Z)-4-amino-2-butenyl)methylamino)-5'-deoxyadenosine (MDL 73811, or AbeAdo) - An inhibitor of S-adenosylmethionine decarboxylase with antitrypanosomal activity.

Brockway AJ, Volkov OA, Cosner CC, MacMillan KS, Wring SA, Richardson TE, Peel M, Phillips MA, De Brabander JK.

Bioorg Med Chem. 2017 Oct 15;25(20):5433-5440. doi: 10.1016/j.bmc.2017.07.063. Epub 2017 Aug 3.

10.

Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.

Moss DM, Domanico P, Watkins M, Park S, Randolph R, Wring S, Rajoli RKR, Hobson J, Rannard S, Siccardi M, Owen A.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00105-17. doi: 10.1128/AAC.00105-17. Print 2017 Jul.

11.

Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay.

Volkov OA, Cosner CC, Brockway AJ, Kramer M, Booker M, Zhong S, Ketcherside A, Wei S, Longgood J, McCoy M, Richardson TE, Wring SA, Peel M, Klinger JD, Posner BA, De Brabander JK, Phillips MA.

ACS Infect Dis. 2017 Jul 14;3(7):512-526. doi: 10.1021/acsinfecdis.7b00022. Epub 2017 Apr 7.

12.

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.

Larkin E, Hager C, Chandra J, Mukherjee PK, Retuerto M, Salem I, Long L, Isham N, Kovanda L, Borroto-Esoda K, Wring S, Angulo D, Ghannoum M.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02396-16. doi: 10.1128/AAC.02396-16. Print 2017 May.

13.

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.

Wring SA, Randolph R, Park S, Abruzzo G, Chen Q, Flattery A, Garrett G, Peel M, Outcalt R, Powell K, Trucksis M, Angulo D, Borroto-Esoda K.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02068-16. doi: 10.1128/AAC.02068-16. Print 2017 Apr.

14.

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.

Scorneaux B, Angulo D, Borroto-Esoda K, Ghannoum M, Peel M, Wring S.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01961-16. doi: 10.1128/AAC.01961-16. Print 2017 Mar.

15.

Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate.

Watkins ME, Wring S, Randolph R, Park S, Powell K, Lutz L, Nowakowski M, Ramabhadran R, Domanico PL.

J Pharm Sci. 2017 Mar;106(3):906-919. doi: 10.1016/j.xphs.2016.12.003. Epub 2016 Dec 14.

16.

Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis.

Wring S, Gaukel E, Nare B, Jacobs R, Beaudet B, Bowling T, Mercer L, Bacchi C, Yarlett N, Randolph R, Parham R, Rewerts C, Platner J, Don R.

Parasitology. 2014 Jan;141(1):104-18. doi: 10.1017/S003118201300098X. Epub 2013 Sep 5. Review.

17.

Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis.

Jacobs RT, Plattner JJ, Nare B, Wring SA, Chen D, Freund Y, Gaukel EG, Orr MD, Perales JB, Jenks M, Noe RA, Sligar JM, Zhang YK, Bacchi CJ, Yarlett N, Don R.

Future Med Chem. 2011 Aug;3(10):1259-78. doi: 10.4155/fmc.11.80.

PMID:
21859301
18.

SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis.

Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, Sligar JM, Jenks MX, Noe RA, Bowling TS, Mercer LT, Rewerts C, Gaukel E, Owens J, Parham R, Randolph R, Beaudet B, Bacchi CJ, Yarlett N, Plattner JJ, Freund Y, Ding C, Akama T, Zhang YK, Brun R, Kaiser M, Scandale I, Don R.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1151. doi: 10.1371/journal.pntd.0001151. Epub 2011 Jun 28.

19.

SAR of 2-amino and 2,4-diamino pyrimidines with in vivo efficacy against Trypanosoma brucei.

Perales JB, Freeman J, Bacchi CJ, Bowling T, Don R, Gaukel E, Mercer L, Moore JA 3rd, Nare B, Nguyen TM, Noe RA, Randolph R, Rewerts C, Wring SA, Yarlett N, Jacobs RT.

Bioorg Med Chem Lett. 2011 May 15;21(10):2816-9. doi: 10.1016/j.bmcl.2011.03.097. Epub 2011 Apr 1.

PMID:
21507639
20.

Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis.

Nare B, Wring S, Bacchi C, Beaudet B, Bowling T, Brun R, Chen D, Ding C, Freund Y, Gaukel E, Hussain A, Jarnagin K, Jenks M, Kaiser M, Mercer L, Mejia E, Noe A, Orr M, Parham R, Plattner J, Randolph R, Rattendi D, Rewerts C, Sligar J, Yarlett N, Don R, Jacobs R.

Antimicrob Agents Chemother. 2010 Oct;54(10):4379-88. doi: 10.1128/AAC.00498-10. Epub 2010 Jul 26.

21.

SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.

Hopkins S, Scorneaux B, Huang Z, Murray MG, Wring S, Smitley C, Harris R, Erdmann F, Fischer G, Ribeill Y.

Antimicrob Agents Chemother. 2010 Feb;54(2):660-72. doi: 10.1128/AAC.00660-09. Epub 2009 Nov 23.

22.

Method to screen substrates of apical sodium-dependent bile acid transporter.

Rais R, Gonzalez PM, Zheng X, Wring SA, Polli JE.

AAPS J. 2008 Dec;10(4):596-605. doi: 10.1208/s12248-008-9069-9. Epub 2008 Dec 16.

23.

Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.

Price RW, Parham R, Kroll JL, Wring SA, Baker B, Sailstad J, Hoh R, Liegler T, Spudich S, Kuritzkes DR, Deeks SG.

Antivir Ther. 2008;13(3):369-74.

24.

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.

Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.

Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.

26.
27.

Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).

Harris M, Joy R, Larsen G, Valyi M, Walker E, Frick LW, Palmatier RM, Wring SA, Montaner JS.

AIDS. 2006 Mar 21;20(5):719-23.

PMID:
16514302
28.

Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.

Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, Yang E, Serabjit-Singh CJ, Adkison KK, Polli JW.

Pharmacology. 2004 Oct;72(2):92-8.

PMID:
15331914
29.

Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model.

Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh CS.

J Pharm Sci. 2004 Apr;93(4):957-68.

PMID:
14999732
30.

Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.

Tolle-Sander S, Rautio J, Wring S, Polli JW, Polli JE.

Pharm Res. 2003 May;20(5):757-64.

PMID:
12751631
31.

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW.

J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.

PMID:
12438524
32.

Automated quantitative and qualitative analysis of metabolic stability: a process for compound selection during drug discovery.

Wring SA, Silver IS, Serabjit-Singh CJ.

Methods Enzymol. 2002;357:285-95. No abstract available.

PMID:
12424918
33.

Rational use of in vitro P-glycoprotein assays in drug discovery.

Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.

J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.

PMID:
11602674
34.

Influence of passive permeability on apparent P-glycoprotein kinetics.

Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE.

Pharm Res. 2000 Dec;17(12):1456-60.

PMID:
11303953
35.

Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.

Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW.

Drug Metab Dispos. 2001 May;29(5):754-60.

PMID:
11302944
36.

Simultaneous determination of zidovudine and lamivudine in human serum using HPLC with tandem mass spectrometry.

Kenney KB, Wring SA, Carr RM, Wells GN, Dunn JA.

J Pharm Biomed Anal. 2000 Jul;22(6):967-83.

PMID:
10857566
37.

Shorter development of immunoassay for drugs: application of the novel RIMMS technique enables rapid production of monoclonal antibodies to ranitidine.

Wring SA, Kilpatrick KE, Hutchins JT, Witherspoon SM, Ellis B, Jenner WN, Serabjit-Singh C.

J Pharm Biomed Anal. 1999 Apr;19(5):695-707.

PMID:
10698534
39.

Rapid development of affinity matured monoclonal antibodies using RIMMS.

Kilpatrick KE, Wring SA, Walker DH, Macklin MD, Payne JA, Su JL, Champion BR, Caterson B, McIntyre GD.

Hybridoma. 1997 Aug;16(4):381-9.

PMID:
9309429
40.

The production and evaluation of a radioligand and antiserum for the radioimmunoassay of subnanogram per millilitre concentrations of lamivudine.

Wring SA, O'Neill RM, Williams JL, Jenner WN, Daniel MJ, Gray MR, Newman JJ, Wells GN, Sutherland DR.

J Pharm Biomed Anal. 1994 Dec;12(12):1573-83. No abstract available.

PMID:
7696382
41.

Radioimmunoassay for the determination of alosetron in human urine and saliva.

Wring SA, O'Neill RM, Williams JL, Birch HL, Goddard CP, Andrew PD, Jenner WN.

Analyst. 1994 Nov;119(11):2395-401.

PMID:
7872486
42.

A sensitive radioimmunoassay, combined with solid-phase extraction, for the sub-nanogram per ml determination of ondansetron in human plasma.

Wring SA, Rooney RM, Goddard CP, Waterhouse I, Jenner WN.

J Pharm Biomed Anal. 1994 Mar;12(3):361-71.

PMID:
8031936
45.

Supplemental Content

Support Center